AU2009330492A1 - Enzastaurin for the treatment of cancer - Google Patents

Enzastaurin for the treatment of cancer Download PDF

Info

Publication number
AU2009330492A1
AU2009330492A1 AU2009330492A AU2009330492A AU2009330492A1 AU 2009330492 A1 AU2009330492 A1 AU 2009330492A1 AU 2009330492 A AU2009330492 A AU 2009330492A AU 2009330492 A AU2009330492 A AU 2009330492A AU 2009330492 A1 AU2009330492 A1 AU 2009330492A1
Authority
AU
Australia
Prior art keywords
cancer
patient
hdac2
enzastaurin
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009330492A
Other languages
English (en)
Inventor
Gopinath Ganji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2009330492A1 publication Critical patent/AU2009330492A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2009330492A 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer Abandoned AU2009330492A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12245108P 2008-12-15 2008-12-15
US61/122,451 2008-12-15
PCT/US2009/066925 WO2010074936A2 (en) 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2009330492A1 true AU2009330492A1 (en) 2010-07-01

Family

ID=41785627

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009330492A Abandoned AU2009330492A1 (en) 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer

Country Status (11)

Country Link
US (1) US20110288032A1 (cg-RX-API-DMAC7.html)
EP (1) EP2376081A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012512157A (cg-RX-API-DMAC7.html)
KR (1) KR20110084533A (cg-RX-API-DMAC7.html)
CN (1) CN102245184A (cg-RX-API-DMAC7.html)
AU (1) AU2009330492A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922367A2 (cg-RX-API-DMAC7.html)
CA (1) CA2746085A1 (cg-RX-API-DMAC7.html)
EA (1) EA201170821A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011006433A (cg-RX-API-DMAC7.html)
WO (1) WO2010074936A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
WO2013112598A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal caner
WO2013112601A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AU2014290012B2 (en) * 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US20080096923A1 (en) * 2004-07-23 2008-04-24 Aniz Girach Methods For Diagnosing And Treating Diabetic Microvascular Complications
US20090202659A1 (en) * 2005-06-10 2009-08-13 Gimble Jeffrey M Modulation of Peripheral Clocks in Adipose Tissue

Also Published As

Publication number Publication date
CN102245184A (zh) 2011-11-16
KR20110084533A (ko) 2011-07-25
US20110288032A1 (en) 2011-11-24
CA2746085A1 (en) 2010-07-01
WO2010074936A2 (en) 2010-07-01
WO2010074936A3 (en) 2010-09-16
EP2376081A2 (en) 2011-10-19
MX2011006433A (es) 2011-07-19
EA201170821A1 (ru) 2011-12-30
JP2012512157A (ja) 2012-05-31
BRPI0922367A2 (pt) 2016-05-24

Similar Documents

Publication Publication Date Title
Pan et al. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
Thatikonda et al. Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Lissanu Deribe et al. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
Agnihotri et al. Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
Lu et al. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
US20110288032A1 (en) Enzastaurin for the treatment of cancer
Mazur et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Du et al. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer
Wang et al. LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis
Hsu et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer
Shah et al. Targeting ribonucleotide reductase M2 and NF-κB activation with didox to circumvent tamoxifen resistance in breast cancer
Li et al. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer
US20150025017A1 (en) Compositions and methods for treating cancer
Hou et al. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer
Rao et al. Long noncoding RNA NEAT1 promotes tumorigenesis in H. pylori gastric cancer by sponging miR‐30a to regulate COX‐2/BCL9 pathway
Wang et al. Single‐cell profiling‐guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
Wang et al. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
Pei et al. Epigenetic regulator KDM4A activates Notch1-NICD-dependent signaling to drive tumorigenesis and metastasis in breast cancer
Lai et al. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma
Pan et al. AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p
WO2020051342A1 (en) Methods for treating metastatic disease using ribosome biogenesis inhibitor cx 5461
Yang et al. RETRACTED ARTICLE: MicroRNA-559 plays an inhibitory role in the malignant progression of glioblastoma cells by directly targeting metadherin
EP4244391A1 (en) Methods and compositions for predicting and treating uveal melanoma
KR101999476B1 (ko) Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법
Wu et al. Mitochondrial p32-mediated regulation of p-TBK1 affects the radiosensitivity of colorectal cancer

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application